Business Context and Reporting Period
This Form 8-K is a current report filed by Mast Therapeutics, Inc. (not Savara Inc.) on March 2, 2015, regarding events occurring on February 28, 2015. The filing addresses the departure of a senior executive and related compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and contractual terms rather than financial performance.
Material Changes
- Executive Departure: Patrick L. Keran departed the Company as President, Chief Operating Officer, and Secretary effective February 28, 2015.
- Stock Option Extension: Mr. Keran was granted an extension until August 28, 2016, to exercise vested portions of outstanding stock options with an exercise price of $13.50 or less.
- Severance Terms: Mr. Keran is eligible for a lump sum severance payment under the Retention and Severance Plan dated July 21, 2009.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future business operations. The primary contingency noted is that the stock option extension and severance payment are conditional upon Mr. Keran delivering and not revoking a general release of claims against the Company.
Investor Verification Checklist
- Verify the full text of the Amendment of Stock Option Agreements, which is scheduled to be filed as an exhibit to the Form 10-Q for the period ending March 31, 2015.
- Review the Retention and Severance Plan (filed July 22, 2009) to confirm the specific calculation of the lump sum severance payment.
- Confirm the status of the general release of claims required to trigger the severance and option extension.